Psoriatic arthritis: current therapy and future directions

Bibliography

• Van Kujik Aw, Reinders-Blankert P, Seets TJ, et al. Detailed analysis of the cell infiltrate and the express of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65:1551-7
   Google Scholar
• Kruithof E, Van den Bossche V, De Rycke L, et al. Distinct synovial immunopathologic characteristics of juvenile-onset spondyloarthritis and other forms of juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2594-604
   Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloartropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18(7):1069-76
   PubMed Web of Science ®Google Scholar
• Chimenti MA, Ballanti E, Perricone C, et al. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmune Rev 2013;12(5):599-606
   PubMed Web of Science ®Google Scholar
• Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheum 2010;28(S61):s132-7
   Google Scholar
• Chandran V, Gladmann DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010;12:288-94
   PubMedGoogle Scholar
• Vander CB, Hoffman IE, Zmierczak H, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Arthritis Rheum 2007;57:1560-3
   Google Scholar
• Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis; development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheum 2001;9(Suppl 22):S17-20
   Google Scholar
• Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010;49(7):1367-73
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Gladman DD. Reprisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008;35(3):469-71
   PubMed Web of Science ®Google Scholar
• Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutic approach in early psoriatic arthritis: results of a pilot randomized 6 month trial with methotrexate. Clin Rheumatol 2008;27:823-6
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. and IMPACT 2 trial investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Krueger GG, Beutler A, et al. and IMPACT 2 study group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT2 trial. Ann Rheum Dis 2007;66:498-505
   PubMed Web of Science ®Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368-77
   PubMed Web of Science ®Google Scholar
• Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naïve patients: the RESPOND study. Ann Rheum Dis 2012;71(4):541-8
   PubMed Web of Science ®Google Scholar
• Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 2013;65(3):464-70
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004;50(6):1939-50
   PubMed Web of Science ®Google Scholar
• Sakellariou GT, Sayegh FE, Anastasilakis AD, et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheum Int 2012; published online Nov 2012 Web. 06 Nov. 2012; doi:10.1007/s00296-012-2534-x
   Google Scholar
• Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthopathies. Arthritis Rheum 1999;25:1957-61
   Google Scholar
• Gupta AK, Grober JS, Hamilton TA. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22(5):894-8
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AWR, Westhovens R, et al. A randomized double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporine in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64
   PubMed Web of Science ®Google Scholar
• Ceponis A, Kavanaugh A. Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg 2010;29(1):56-62
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Prinz J, Gottlieb A. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33(7):1147-451
   Google Scholar
• Salvarani C, Pipitone N, Catanoso M, et al. Adalimumab in Psoriatic arthritis. J Rheumatol 2012;39(S89):77-81
   Google Scholar
• Spadaro A, Lubrano E, Ferrara NM, et al. Etanercept in psoriatic arthritis. J Rheumatol 2012;39(S89):74-6
   Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Infliximab in psoriatic arthritis. J Rheumatol 2012;39(S89):71-3
   Google Scholar
• Atteno M, Peluso R, Costa L. Comparison of effectiveness and safety of Infliximab, etanercept and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying anti-rheumatic drugs. Clin Rheumatol 2010;29(4):399-403
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Avina-Zubieta JA, et al. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirects comparison meta-analysis. Biologics 2012;6:417-27
   PubMedGoogle Scholar
• Mease P, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with and without prior anti-tnf exposure: 24 week results of a phase 3 double-blind randomized placebo-controlled study. ACR 2012;abstract 2613
   Google Scholar
• Cantini F, Niccoli L, Cassara E, et al. Sustained maintenance of clinical emission after adalimumab dose reduction in patients with early psoriatic arthritis: a long term follow-up study. Biologics 2012;6:201-6
   PubMedGoogle Scholar
• Papp KA, Langley RG, Sigurgeirsson MA, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II does-ranging study. Br J Dermatol 2013;168(2):412-21
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9
   PubMed Web of Science ®Google Scholar
• Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomized, double blind, placebo controlled, phase II proof of concept trial. Ann Rheum Dis 2013;0:1-8
   Google Scholar
• McInnes I, Kavanaught A, Gottlieb A, et al. Ustekinumb in patients with active psoriatic arthritis: results of the phase 3, multicenter,double-blind, placebo-controlled PSUMMIT I Study. Ann Rheum Dis 2012;71:S107
   Web of Science ®Google Scholar
• Ritchlin C, Gottlieb A, McInnes I, et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-tnf agents: results of a phase III, multicenter double-blind, placebo controlled study. ACR 2012;abstract 2557
   Google Scholar
• Schett G, Wollenhautpt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64(10):3156-67
   PubMed Web of Science ®Google Scholar
• Westhovens R, Kremer J, Moreland L, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiing background methotrexate: a 5 year extended phase IIB study. J Rheumatol 2009;36:736-42
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladsein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63(4):939-48
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): results of phase II international, multicenter, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 2012;1(S3):110
   Google Scholar
• Ogata A, Umegaki N, Katavama I. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85-7
   PubMed Web of Science ®Google Scholar
• Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2013; published online 7 Jan 2013; doi:10.1111/jdv.12081
   Google Scholar
• Canete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid aggregates in psoriatic arthritis. Ann Rheum Dis 2007;66:720-6
   PubMed Web of Science ®Google Scholar
• Wendling D, Dougados M, Berenbaum F, et al. A nationwide series: data from the AIR registry of the French Society of rheumatology. J Rheumatol 2012;39:2327-31
   PubMed Web of Science ®Google Scholar
• Mease P, Kavanaugh A, Genovese M, et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions [abstract]. Arthritis Rheum 2010;62(Suppl):S818
   Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four week clinical trial. Arthritis Rheum 2012;62:1290-7
   Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
   PubMed Web of Science ®Google Scholar
• Antoni C, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol 2008;35(5):869-76
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2 year data from the adalimumab effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Rtichlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, van der Heijde D, McInnes I, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a randomized, placebo-controlled trial. Arthritis Rheum 2012;64(8):2504-17
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mcinnes I, Mease P, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized placebo-controlled GO-REVEAL study. Ann Rheum Dis 2012(0):1-10
   Google Scholar
• Gisondi P, Tinazzi P, El-dalati G, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital based case control study. Ann Rheum dis 2008;67:26-30
   PubMed Web of Science ®Google Scholar
• Wagner CL, Visvanathan S, Elashoff M, et al. Markers of inflammation and bone remodeling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis 2013;72:83-8
   PubMed Web of Science ®Google Scholar